<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721562</url>
  </required_header>
  <id_info>
    <org_study_id>ARGO</org_study_id>
    <nct_id>NCT03721562</nct_id>
  </id_info>
  <brief_title>Antibiotic Resistance in Global Pediatric Oncology Centers</brief_title>
  <official_title>Antibiotic Resistance in Global Pediatric Oncology Centers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tarleton State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antibiotic resistance is one of the major health threats facing global as well as domestic
      populations, however it is not well characterized in pediatric patients. Pediatric patients
      receiving cancer-directed therapy have several risk factors implicated in development of
      antibiotic resistance including multiple courses of antibiotics, repeated exposures to the
      hospital environment, indwelling devices and chemotherapy-related damage to mucosal barriers.
      The investigators propose to capitalize upon the unique position of St. Jude Global within
      the global pediatric oncology community by using its regional alliance network to describe
      the molecular epidemiology of antibiotic resistance in Gram-negative bacteria in this
      population.

      Primary Objectives

        1. Describe the epidemiology and the phenotypic and previously determined molecular
           determinants of antimicrobial resistance in Gram-negative organisms isolated from
           pediatric diagnostic specimens in selected Central American and US sites with capacity
           to treat pediatric cancer

        2. Utilize strain typing by whole genome sequencing to describe relatedness between
           organisms at participating sites
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participating clinical microbiology laboratories will flag any Gram-negative bacteria meeting
      inclusion criteria. Bacteria will be subcultured; one sample will be lysed and shipped to St.
      Jude; the remaining sample will be stored onsite for the duration of the study. Samples of
      bacteria from both oncology and non-oncology patients will be included. Whole genome
      sequencing will be performed on the bacterial samples at St. Jude and the genotypic and
      phenotypic antimicrobial resistance testing (AST) results compared. Genotypic results will
      additionally be used to describe phylogenetic relationships and potential transmission events
      both within and between sites.

      Each participating location will collect limited clinical data corresponding to disease and
      treatment related factors on the affected patient. This will include sociodemographic
      variables, oncologic diagnosis, treatment phase, presence of a central venous catheter or
      other foreign body, antibiotic treatment within the past month, and previous history of
      colonization or infection by a resistant organism.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patterns of organism and resistance in participating sites</measure>
    <time_frame>approximately 6 months after completion of data collection</time_frame>
    <description>Number of isolated organisms by anatomic site and geographic site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patterns of organism and resistance in participating sites</measure>
    <time_frame>approximately 6 months after completion of data collection</time_frame>
    <description>Number of antibiotic resistance genes/mutations of interest by geographic site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patterns of organism and resistance in participating sites</measure>
    <time_frame>approximately 6 months after completion of data collection</time_frame>
    <description>Correlation of known mutations/genes of interest with drug resistance phenotype</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic relatedness between bacteria at participating sites</measure>
    <time_frame>approximately 6 months after completion of data collection</time_frame>
    <description>Whole genome sequencing results will be used to describe whether isolated organisms appear to be related phylogenetically.</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Antibiotic Resistant Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric (0-18 years of age) patients having a bacteria isolated from a sterile site
        (blood, cerebrospinal fluid, body fluid) or urine positive for a Gram-negative bacteria
        nonsusceptible to at least 1 of the following: third generation cephalosporin, fourth
        generation cephalosporin or carbapenem OR screening positive for carbapenemase or extended
        spectrum beta lactamase (ESBL) production.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric (0-18 years of age) patients having a bacteria isolated from a sterile site
             (blood, cerebrospinal fluid, body fluid) or urine positive for a Gram-negative
             bacteria nonsusceptible to at least 1 of the following: third generation
             cephalosporin, fourth generation cephalosporin or carbapenem OR screening positive for
             carbapenemase or extended spectrum beta lactamase (ESBL) production.

        Exclusion Criteria:

          -  Repeated isolation of the same organism from the same patient within the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheena Mukkada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheena Mukkada, MD</last_name>
    <phone>866-278-5835</phone>
    <email>referralinfo@stjude.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheena Mukkada, MD</last_name>
      <phone>866-278-5833</phone>
      <email>referralinfo@stjude.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James J. Dunn, Ph.D.</last_name>
      <phone>832-824-2662</phone>
      <email>jjdunn@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>James J. Dunn, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional de Niños Benjamín Bloom</name>
      <address>
        <city>El Salvador</city>
        <country>El Salvador</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo E. Barahona, MD</last_name>
      <phone>503-7140-1277</phone>
      <email>guille_barahona@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Guillermo E. Barahona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unidad Nacional de Oncología Pediátrica</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomás R. Letona, MD</last_name>
      <phone>502-3027-5187</phone>
      <email>tletona@unop.org.gt</email>
    </contact>
    <investigator>
      <last_name>Tomás R. Letona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Niño</name>
      <address>
        <city>Panamá</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dora I. Estripeaut, MD</last_name>
      <phone>507-6747-5646</phone>
      <email>destripeaut@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dora I. Estripeaut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>El Salvador</country>
    <country>Guatemala</country>
    <country>Panama</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibiotic Resistance</keyword>
  <keyword>Gram Negative Bacteria</keyword>
  <keyword>Pediatric Patients</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

